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The viral infectivity factor (Vif) of human immunodeficiency virus type-1 (HIV-1) functions at a late stage of the viral life cycle
to confer infectivity on progeny virions. Although Vif is present in HIV-1 particles, both the relevance of incorporation for
function and the mechanism that underlies incorporation remain unresolved. Using matched T cell systems that express high
or low levels of Vif, we demonstrate that the extent of Vif incorporation into virions varies in relation to cellular expression
levels. Because viral infectivity is not affected by these variations, we suggest that the packaging of Vif is neither specific nor
necessary for function. © 1998 Academic Press
INTRODUCTION
Lentiviruses can be distinguished from oncoretrovi-
ruses in part because they encode a number of regula-
tory and accessory genes that are additional to the gag,
pol, and env genes common to all replication competent
retroviruses. One of these genes, vif, is encoded by all
lentiviruses with the exception of equine infectious ane-
mia virus (Oberste and Gonda, 1992) and has been
shown to be essential for virus replication in primary
cells and certain cell lines as well as in vivo (Sodroski et
al. 1986; Fisher et al. 1987; Strebel et al. 1987; Fan and
Peden, 1992; Gabuzda et al. 1992; Sakai et al. 1993; Sova
and Solsky, 1993; von Schwedler et al. 1993; Gibbs et al.
1994; Borman et al. 1995; Courcoul et al. 1995; Simon et
al. 1995; Harmache et al. 1996; Simon and Malim, 1996).
Vif appears to function at a late stage in the viral life
cycle—such as assembly, budding, or maturation—and
thereby exerts a profound influence on the infectivity of
progeny virions (von Schwedler et al. 1993; Borman et al.
1995; Courcoul et al. 1995; Fouchier et al. 1996; Simon
and Malim, 1996). More specifically, virions that are pro-
duced in the absence of Vif are severely debilitated in
their ability to form proviruses during the next round of
infection. It has previously been suggested that this is
due to an instability of postentry viral nucleoprotein com-
plexes which ultimately results in the loss of viral nucleic
acids prior to provirus establishment (Goncalves et al.
1996; Simon and Malim, 1996).
Western blot analyses of gradient purified HIV-1 viri-
ons have demonstrated that at least three accessory
gene products, Nef (Pandori et al. 1996; Welker et al.
1996; Bukovsky et al. 1997; Miller et al. 1997), Vpr (Cohen
et al. 1990; Lu et al. 1993; Paxton et al. 1993), and Vif
(Borman et al. 1995; Liu et al. 1995; Camaur and Trono,
1996; Fouchier et al. 1996; Karczewski and Strebel, 1996),
are incorporated into viral particles. However, the spec-
ificity of packaging has only been demonstrated for Vpr,
with the determinants of encapsidation having been
mapped to the amino-terminal region of Vpr (Ma-
halingam et al. 1995, 1997) and the p6 domain of p55Gag
(Paxton et al. 1993; Lavallee et al. 1994; Checroune et al.
1995; Kondo et al. 1995; Lu et al. 1995). Although incor-
poration of Vif into virions has been demonstrated for
HIV-1 (Borman et al. 1995; Liu et al. 1995; Camaur and
Trono, 1996; Fouchier et al. 1996; Karczewski and Strebel,
1996) and simian immunodeficiency virus derived from
sooty mangabee monkeys (SIVSM) (Liu et al. 1995), it has
also been shown that the Vif protein of HIV-1 can be
incorporated into murine leukemia virus (MLV) particles
(Camaur and Trono, 1996). Because MLV does not have
a vif gene, this finding suggests that incorporation of Vif
into virons may not be specific.
Previous analyses have demonstrated that although
Vif and Gag are expressed in roughly equimolar amounts
in HIV-1-infected T cells, the ratio of Vif to Gag in virions
ranges from 1:30 to 1:80 (Fouchier et al. 1996). The
disparity between these ratios, together with the obser-
vation that a substantial fraction of Vif colocalizes with
Gag in the cytoplasm of infected cells (Simon et al. 1997),
suggest that Vif may be incorporated into virions by
virtue of its relative abundance at the site of budding. The
fact that MLV, like HIV-1, assembles at the plasma mem-
brane (Bolognesi et al. 1978; Gelderblom, 1991) and also
encapsidates HIV-1 Vif (Camaur and Trono, 1996) is con-
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sistent with this notion. To address the relevance of Vif
incorporation into virions, we have determined, first,
whether this process can be influenced by cellular ex-
pression levels of Vif and, second, whether infectivity of
virions can be modulated by the number of Vif molecules
incorporated into virions.
RESULTS
An important issue that needs to be addressed regard-
ing Vif function is the relevance of virion incorporation to
viral infectivity. If Vif was to be targeted specifically into
virions [for example, by interacting with virion compo-
nents (Bouyac et al. 1997)], it might be expected that
reducing the level of Vif in virus-producing cells would
not significantly affect the amount of Vif in virions. Con-
versely, if the incorporation of Vif into virions was to be an
‘‘indirect’’ consequence of its localization at the site of
assembly, then it might be predicted that the ratio of Vif
to Gag in viral particles would alter in response to
changes in cellular expression levels. Moreover, the lat-
ter scenario could be extended to predict that changes in
Vif incorporation would not impact on virus infectivity.
To address these questions, the protein compositions
(Fig. 1 and Table 1) and infectivities (Fig. 3) of HIV-1
virions expressed in two acutely infected cultures of
human T cells were examined. In the first culture, paren-
tal H9 cells were infected with wild-type (Vif-expressing)
HIV-1; in the second culture, H9 cells that had been
modified to express the HIV-1 Vif protein (H9/hVif) were
infected with HIV-1 that was genotypically vif-deficient
FIG. 1. Quantitation of Vif and Gag in infected cell lysates (A) and purified virions (B) by Western blot analysis. Cultures of H9 or H9/hVif cells were
infected with wild-type HIV-1 or HIV-1/Dvif, respectively, and the viruses harvested and purified at the time of peak production. Whole cells were also
lysed at the time of virus harvest. Recombinant proteins purified from Escherichia coli were used as standard curves for quantitation. Cell lysates
corresponding to ;5 3 105 cells were loaded in each well, and virus preparations corresponding to ;3.5 and ;350 ng of p24Gag were used for
quantitation of Gag and Vif, respectively. The right-hand edge of the barely visible Vif band is marked.
TABLE 1
Quantitation of Gag and Vif in Virions and Infected Cells
a The amount of Vif in each sample was determined as described
(Fouchier et al., 1996) using the dilution series of recombinant protein
(Fig. 1) together with the calculated relative molecular masses of native
and recombinant proteins and densitometry.
b The total amount of Gag (including p55 and p24) was determined as
for Vif using a p24Gag (capsid, CA) reactive antibody. Note that the quan-
tities of virions used for analyses of Gag were only 1% of those used for Vif.
c Molar ratios were calculated using the calculated molecular
masses of Vif and Gag.
d Based on the assumption that there are 2750 p24Gag monomers per
retroviral particle (Arthur et al., 1992). NA, not applicable.
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(HIV-1/Dvif ) (Simon et al. 1995). Since H9/hVif cells were
derived using the retroviral vector LM-N/hVif (Simon et al.
1995), Vif expression in these cells was regulated by the
relatively weak (compared to HIV-1) U3 long terminal
repeat (LTR) enhancer element of Moloney (Mo) MLV.
With respect to Vif expression levels, and as will become
evident below, the first culture constitutes a ‘‘high expres-
sor‘‘ whereas the second constitutes a ‘‘low expresser.’’
Following the establishment of these two infections
and at a time when virus production was close to its
maximum, approximately equal quantities of virus (as
determined by supernatant reverse transcriptase activity,
data not shown) were harvested and purified using con-
tinuous sucrose gradients (Fouchier et al. 1996). Pelleted
virions from the peak gradients fractions (Fig. 1B) as well
as whole cell lysates of the virus-producing cells (Fig.
1A) were subjected to Western blot analyses to deter-
mine the levels of Gag (p55Gag and p24Gag) and Vif in all
samples; these values are shown in Table 1 together
with the ratio of Vif to Gag and the calculated average
number of Vif molecules per virion. As previously shown,
the ratios of Vif to Gag for a culture infected with wild-
type virus were far greater within cells than in viral
particles (1:1.7 vs 1:100; Fig. 1, lane 6) (Fouchier et al.
1996). In contrast, for the H9/hVif cells that were infected
with HIV-1/Dvif, both of the Vif to Gag ratios were sub-
stantially reduced (1:11 for cell lysates; 1:810 or 1:350 for
virions in two separate experiments: Figs. 1, lane 7, and
2, lane 8, respectively). These ratios equate to average
virion incorporation levels of 28 and 3.4 or 7.8 molecules
of Vif per particle for wild-type virus expressed in H9
cells and Dvif virus expressed in H9/hVif cells, respec-
tively. Thus when the level of cell associated Vif is re-
duced by ;6.5-fold (i.e., 11/1.7) in the low expresser
H9/hVif cells, the extent of Vif incorporation drops by a
corresponding four- to eightfold (350–810/100). It there-
fore appears that the number of Vif molecules present
per virion is dependent upon cellular expression levels.
It has previously been shown that vesicles containing
cellular material can contaminate virion preparations of
HIV-1 even after purification through sucrose density
gradients (Bess et al., 1997; Gluschankof et al., 1997). To
determine whether the Vif detected in our virus prepara-
tions was incorporated into virions or into cosedimenting
cellular vesicles, culture supernatants from uninfected
and HIV-1/Dvif-infected H9/hVif cells were harvested and
subjected to sucrose density gradient purification as
before. Fractions that contained peak levels of virus
together with the corresponding fractions from the unin-
fected cell gradients were centrifuged at 75,000 g, and
their pellets examined for Gag and Vif content (Fig. 2). As
expected, the levels of Vif were equivalent in the cell
lysates of infected and uninfected H9/hVif cultures. In
contrast, examination of the ‘‘virus’’ fractions of the gra-
dients revealed that Vif was only present in samples
derived from infected cells. We have concluded, there-
fore, that Vif is not incorporated into contaminating ves-
icles but, rather, into virions. Of note, this would be
consistent with previous results showing that Vif is as-
sociated with membrane-free cores of HIV-1 and SIVSM
(Liu et al. 1995; Karczewski and Strebel, 1996).
Having shown that it was possible to manipulate the
levels of Vif in HIV-1 virions, the consequences of such
alterations for virus infectivity were evaluated in single
cycle challenges of the indicator cell line C8166/HIV-CAT
(Fig. 3). Samples of the culture supernatants used above
to examine protein composition (Fig. 1) were therefore,
normalized according to reverse transcriptase content
and used to challenge the indicator cells. At 24 h, the
levels of CAT expression were determined in the cell
lysates and compared to an uninfected control culture.
FIG. 2. Quantitation of Vif in cell lysates and purified cell culture
supernatants from infected and uninfected H9/hVif cells by Western
blot analysis. Whole cell lysates and virus or matching uninfected cell
supernatant were prepared and analyzed as described in Fig. 1.
FIG. 3. Measurement of viral infectivity in single cycle challenges. (A)
HIV-1 from H9 cells and HIV-1/Dvif from H9/hVif cells were quantitated
by reverse transcriptase levels and equal amounts were used to infect
0.5 3 106 C8166/HIV-CAT indicator cells. After a 24-h incubation, the
infected cells were lysed, together with an uninfected control, and the
levels of CAT activity determined. (B) As a control, the infectivities of
equal amounts of HIV-1 and HIV-1/Dvif produced by initial high titer
infections of parental H9 cells were also determined.
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As shown in Fig. 3A, HIV-1/Dvif produced from H9/hVif
cells and wild-type virus derived from parental H9 cells
displayed approximately equivalent infectivities in this
representative set of challenges. We have therefore con-
cluded that a substantial decrease in the Vif content of
HIV-1 viral particles has no significant functional out-
come with respect to viral infectivity. As an additional
control, we also challenged the indicator cells with HIV-1
and HIV-1/Dvif produced from parental H9 cells (Fig. 3B).
As reported previously, the wild-type virus was [dim]100-
fold more infectious than its vif-deficient counterpart
(Fouchier et al. 1996; Simon and Malim, 1996); this further
confirmed the efficient functional complementation of
HIV-1/Dvif by the H9/hVif cells.
DISCUSSION
The results presented here imply that the incorpo-
ration of Vif into HIV-1 virions is determined by the
level of Vif in virus producer cells and not by specific
signals residing in either Vif or other viral components.
Because Vif appears to be localized to the site(s) of
virus assembly and budding (Simon et al. 1997), we
propose that it is packaged by a nonspecific mecha-
nism whose efficiency is determined by local concen-
tration; this would be consistent with the proportional
variation between virion incorporation and cellular ex-
pression level that was observed in these experiments
(Fig. 1 and Table 1). This contrasts with the virion
content of the Gag proteins and genomic RNA; the
copy numbers of these essential virion components
are relatively constant and are not, therefore, propor-
tional to cellular expression levels.
The observation that virus infectivity was not af-
fected by a significant alteration in Vif content also
supports (but does not prove) the hypothesis that the
presence of Vif in virions may not directly contribute to
its modulation of infectivity. This underscores the no-
tion that Vif probably functions during assembly and
budding (Gabuzda et al. 1992; von Schwedler et al.
1993) rather than within cell-free virions or infected
target cells. Accordingly, analyzing the effects of Vif in
virus-expressing cells will continue to be critical for
understanding the function of this family of essential
lentiviral proteins.
Interestingly, examination of the incorporation of
cyclophilin A into HIV-1 particles has also shown that
variations in cellular expression levels alter packaging
efficiency even though packaging is determined by a
specific interaction with p24Gag (Luban et al. 1993).
However, in marked contrast to our findings with Vif,
virions that contained reduced levels of cyclophilin A
displayed reduced infectivities (Braaten et al. 1996;
Briggs et al. 1996).
MATERIALS AND METHODS
Cell lines and viruses
H9/hVif cells, which stably express HIV-1 Vif, and the
C8166/HIV-CAT indicator cell line have been previously
described. Virus stocks were generated by transfection
of 293T cells with an infectious molecular clone of wild-
type HIV-1 (pIIIB) or its vif-deficient derivative, HIV-1/Dvif
(pIIIB/Dvif). After 24 h, the virus containing culture super-
natants were clarified by centrifugation at 500 g, filtered
through 0.45-mm filters and stored at 280°C in 1-ml
aliquots.
Purification of virions
Culture supernatants were harvested at the time of
peak virus production and clarified as described above.
An aliquot was put aside for the determination of infec-
tivity, and the remainder was purified using 20–60% (w/v)
sucrose density gradients (Fouchier et al. 1996). Frac-
tions were collected from the gradients and subjected to
reverse transcriptase analysis. Viruses were pelleted
from the fractions that contained peak levels of reverse
transcriptase activity and were then lysed for Western
blot analysis (Fouchier et al. 1996).
Western blot analyses
Virion and whole cell lysates were resolved by so-
dium dodecyl sulfate (SDS)–polyacrylamide gel elec-
trophoresis and then transferred to nitrocellulose fil-
ters. The filters were subjected to Western blot anal-
ysis using mouse monoclonal antibodies raised
against p24Gag (Fouchier et al. 1996) or Vif (Simon et al.
1995). Bound antibodies were then detected using
horseradish peroxidase-conjugated anti-mouse anti-
bodies, enhanced chemiluminescence and autora-
diography. The levels of Gag (p55Gag and p24Gag) and
Vif in all samples were quantitated by densitometry
using dilutions of purified recombinant p24Gag or Vif as
standard curves (Fourchier et al. 1996).
Infectivity assays
Virus stocks were normalized according to reverse
transcriptase activity and infectivities were evaluated
in single-cycle challenges of the indicator cell line
C8166/HIV-CAT (Simon and Malim, 1996). These cells
harbor the bacterial chloramphenicol acetyl trans-
ferase (CAT) gene under the transcriptional control of
the HIV-1 promoter. As a result, the expression of CAT
is induced by Tat produced from newly formed provi-
ruses and serves as a sensitive indicator of viral
infectivity. Twenty-four hours after virus exposure, the
levels of CAT expression were determined in the cell
lysates and compared to an uninfected control culture
(Simon and Malim, 1996).
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